

17th May, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051
Scrip Code: NSE - KILITCH

Sub: Intimation of the Board Meeting of the Company to consider the Financial Results for the quarter and financial year ended 31st March, 2022

Dear Sir/Madam,

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Meeting of the Board of Directors of the Company will be held on Thursday, 26th May, 2022 inter-alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2022.


Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE, the Trading Window has been closed with effect from 1st April, 2022 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**



Mukund Mehta
Managing Director

